Open science can be best defined as the practice of science across all disciplines such that others can collaborate and contribute, and where research data and processes are freely available, under terms that enable reuse, redistribution and reproduction. This includes includes peer-reviewed publications, data repositories, workflow and collaboration tools. Open science is driven and governed by science policies and mandates.
Pharmaceutical companies, which fund approximately half of all biomedical research, are now leaders in the publication and disclosure of research. However, access to much company-funded research is still restricted by journal paywalls. Therefore, with open science continuing to rise in prominence and adoption by science funders and researchers, how can pharmaceutical companies play their part?
This episode was part of a podcast series funded by Pfizer to celebrate 2021 International Open Access Week. The series interviewed experts working within clinical and medical disciplines who shared their perspectives on the impact and benefit of open science for patients and key stakeholders.
My guest for today’s podcast is Dr Joana Osório, Communications Consultant for a global collaboration called Open Pharma. Open Pharma aims to improve the pharma publications model by connecting pharma with innovations in publishing to increase transparency and access to research outputs.